Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its CRO, SMO and CSO operations. As CEO of EPS Group’s subsidiary company EPS China Group, Yan also outlines the China Group’s recent milestones, how the company can be a bridge between Japan, Europe, the USA and China, and the opportunities for collaboration between Japanese and Chinese companies.
Yan Hao – Chairman and CEO, EPS Group; CEO, EPS China Group
24.04.2019
Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its CRO, SMO and CSO operations. As CEO of EPS Group’s subsidiary company EPS China Group, Yan also outlines the China Group’s recent milestones, how the company can be a bridge between Japan, Europe, the USA and China, and the opportunities for collaboration between Japanese and Chinese companies.
Related Interviews
Sizhen Wang – CEO & Co-Founder, Genetron Health
Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen…
Dun Yang – President & CEO, Anticancer Bioscience
Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world,…
China / Emerging Pharmacovigilance Framework Ensuring Safe COVID-19 Vaccines
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
China / 61.7% Profit Hit Needed for NDRL Listing; Local mRNA Rush; BioNTech Continues Push for Vaccine Approval
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
Global / PharmaBoardroom’s Top Five Op-Eds of 2021
PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca…
Latest Report
